Sodium glucose transporters are proteins responsible for reabsorption of glucose from kidneys. This protein family has two members: sodium glucose cotransporter-1 (SGLT1) and sodium glucose cotransporter-2 (SGLT2). SGLT2 is expected to reabsorb 90% of the glucose from kidneys, while SGLT1 absorbs the remaining 10%. SGLT2 inhibitors are drugs that affect the action of SGLT2 proteins, thereby reducing blood glucose levels. Hence, these are important in the treatment for type II diabetes. SGLT2 inhibitors called glifozins have four members: canaglifozin, dapaglifozins, ipraglifozin, and empaglifozins. Canaglifozin are most widely used and found to have more affinity toward SGLT2. Besides reducing the blood glucose level, it also lowers blood pressure and promotes weight loss.
SGLT2 inhibitors are expected to have high consumption in the near future due to simple treatment method and relatively better results and preferred line of treatment for type II diabetes. Additionally, rising prevalence of diabetes across the globe is expected to drive the global SGLT2 inhibitors market. According to the American Diabetes Association, approximately 25.8 million people were diagnosed with diabetes in 2010 which increased to 29.1 million in 2012 in the U.S. According to a study conducted by the organization based on World Health Organization Data worldwide, prevalence of diabetes is expected to rise from 2.8% in 2000 to 4.4% by 2030. This exponential growth in diabetic population is expected to drive the global SGLT2 inhibitors market. However, the contra-indications associated with SGLT2 inhibitors treatment and patient selection criteria are the factors expected to boost the growth of the global SGLT2 inhibitors market. Furthermore, there are very few generic alternatives available for the drug which limits its access across the regions. This hampers the growth of the market.
Based on inhibitor molecule, three SGLT2 inhibitors have been approved and recommended in type II diabetes. These are canaglifozin, dapaglifozin, and empaglifozin. These drugs differ on their patient selection and related side effects. For instance, canaglifozin has a concern of hyperkalemia while dapaglifozin has concern in development of bladder cancer and accordingly the patient selection of these treatment types differ. All of the SGLT2 inhibitors are administered orally; however, their kinetics and time of action differ. Canaglifozin is the most widely used among other SGLT2 inhibitors, and very few generic brands are available in the markets for this drug. Dapaglifozin has no generic brands available in the market and is marketed by Boehringer Ingelheim GmbH.
In terms of region, the global SGLT2 inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for major share of the global SGLT2 inhibitors market. The market in the region is expected to grow at higher rate owing to rising prevalence of diabetes and well-established health care infrastructure. Europe is expected to hold the second largest share of the global SGLT2 inhibitors market driven by growing industry and stringent manufacturing rules and regulations. The SGLT2 inhibitors market in Asia Pacific is projected to witness a promising growth in the near future led by emerging markets such as India and China.
Major players in the SGLT2 inhibitors market are Boehringer Ingelheim GmbH, Janssen Pharmaceutical (part of Johnson & Johnson), GRUPO TECNIMEDE, Unichem Laboratories Ltd., Edifício Bluepharma, and AstraZeneca Pharmaceuticals LP.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.